Skip to content
Clinical Trials – home

Hospital Universitario San Juan De Alicante

Verified siteinfo

Spain Carretera N-332 Alicante-Valencia S/n, 03550 Sant Joan D'alacant, Spain

  • 10 trials recruiting
  • Asthma · Conjunctivitis allergic · HER2 positive breast cancer
  • Adults and children

About Specializations

Hospital Universitario San Juan De Alicante in Sant Joan D'alacant, Spain specialises in clinical trials of conditions such as Asthma, Conjunctivitis allergic, HER2 positive breast cancer, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Breast Cancer Research

At Hospital Universitario San Juan De Alicante, a major share of the clinical research portfolio focuses on Neoplasms, especially breast cancer. Trials are exploring new treatment options for early, advanced, HER2-positive, HER2-low, and hormone receptor-positive disease, with the aim of improving survival, delaying progression, and refining treatment choices for patients with difficult-to-treat cancers.

  • Advanced triple negative breast cancer and early breast cancer
  • HER2-positive, HER2-low, and HR-positive / HER2-negative breast cancer
  • Brain metastases and metastatic breast cancer
  • Testing newer targeted and immunotherapy-based approaches

This work reflects a strong interest in evaluating therapies that may be more effective than current standard options for breast cancer.

Allergology and Respiratory Disease Studies

The site’s Allergology department is actively involved in research on immune system diseases and respiratory tract diseases, with a clear focus on allergic rhinitis, rhinoconjunctivitis, and asthma. These studies are designed to assess allergen immunotherapy and other treatments that may better control symptoms and improve day-to-day quality of life.

  • Allergic rhinoconjunctivitis with or without controlled asthma
  • Moderate-to-severe allergic rhinitis and pollen-related symptoms
  • House dust mite and grass allergy treatment
  • Evaluating symptom relief and improved allergy control

Research at this hospital is helping advance more personalized care for people living with persistent allergy-related conditions.

Cardiovascular and Metabolic Medicine

Another important area of research covers cardiovascular diseases and nutritional and metabolic diseases. Trials at the site are studying conditions such as myocardial infarction, spontaneous coronary artery dissection, familial hypercholesterolemia, and type 2 diabetes, with the goal of improving prevention, recovery, and long-term disease control.

  • Heart attack and coronary artery complications
  • High cholesterol in children and inherited lipid disorders
  • Diabetes management in patients with renal impairment
  • Assessing better prevention and treatment strategies

These studies support more effective care for patients with chronic cardiometabolic conditions and acute cardiovascular events.

Hematology, Rheumatology, and Immune-Mediated Conditions

The research portfolio also includes hemic and lymphatic diseases and complex immune-related disorders. At Hospital Universitario San Juan De Alicante, trials are investigating haemophilia A and chronic inflammatory rheumatic diseases, while also looking at ways to reduce cardiovascular risk in people with inflammatory conditions.

  • Haemophilia A with factor VIII inhibitors
  • Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and lupus
  • Cardiovascular prevention in inflammatory disease
  • Improving bleeding control and long-term risk management

The overall aim is to test better approaches for managing both disease activity and related complications in these patients.

Critical Care and Serious Infection Research

The site is also involved in studies on pathological conditions, signs and symptoms such as septic shock. This research is focused on improving emergency and intensive care treatment, with the goal of supporting survival and reducing the need for prolonged organ support in severely ill patients.

  • Septic shock and early resuscitation care
  • Testing tailored treatment strategies in critical illness
  • Improving short-term outcomes in intensive care
  • Evaluating more effective supportive care approaches

These trials contribute to better decision-making in critical care medicine for patients with life-threatening infection-related complications.

Translational and Diagnostic Research

Beyond disease-specific treatment studies, the site participates in research on analytical, diagnostic and therapeutic techniques and equipment as well as broader physiological processes. This includes efforts to improve how patients are identified, monitored, and matched to the most appropriate therapy across several specialties.

  • Using diagnostic tools to refine cardiovascular risk assessment
  • Monitoring treatment response in diabetes and allergy care
  • Supporting more precise patient selection for therapy
  • Strengthening evidence for everyday clinical decision-making

The research environment at this Spanish hospital combines treatment-focused trials with studies that aim to improve diagnosis and patient stratification.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Carretera N-332 Alicante-Valencia S/n03550 Sant Joan D'alacantSpain
Recruiting now
10 trials
Conditions studied
24
Partner status
Verified site

More sites in Sant Joan D'alacantSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

24 clinical trials

Breast cancer

Recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Asthma

Recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dermatophagoides farinae, Dermatophagoides pteronyssinus, and Lepidoglyphus destructor Immunotherapy for Allergic Rhinitis and Rhinoconjunctivitis in Patients With or Without Mild Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Allergen extracts
  • Sponsor:Inmunotek S.L.

Study of cardiovascular disease prevention using carotid ultrasound in patients with inflammatory rheumatic diseases treated with amlodipine, atorvastatin, rosuvastatin, ezetimibe and bempedoic acid

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amlodipine
  • Sponsor:Instituto De Investigacion Marques De Valdecilla

Study on the Effectiveness and Safety of Mannan-Conjugated Allergoids for Treating Allergic Rhinitis/Rhinoconjunctivitis in Patients Allergic to House Dust Mites

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dermatophagoides farinae enriched allergoid, mannan-conjugated, polymerised
  • Sponsor:Inmunotek S.L.

Study on the Safety and Effectiveness of Inclisiran in Children Aged 2 to Under 12 with Homozygous Familial Hypercholesterolemia

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:Emory University

Type 2 diabetes mellitus

Not yet recruiting

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alogliptin
  • Sponsor:Tecnimede-Sociedade Tecnico-Medicinal S.A.

Diabetes mellitus

Not recruiting

Study on Switching to Insulin Glargine 300 U/ml from Insulin Glargine 100 U/ml for Patients with Type 2 Diabetes and Kidney Problems

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Sanofi Aventis S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.